CEPT1

Across TCGA pan-cancer cohorts, CEPT1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CEPT1 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CEPT1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CEPT1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and COAD show a favorable association.

HNSC, COAD, and LUAD are the cancer types where CEPT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.891	0.654	<.001	70	view →
COAD	DFS	Median	III,IV	1.000	0.893	.033	24	view →
LUAD	OS	Tertile	All	0.550	0.909	.015	8	view →
LSCC	DFS	Median	All	0.907	0.464	.009	4	view →
GBM	OS	Quartile	All	0.306	0.562	.016	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CEPT1–HNSC (DFS)

Open the HNSC breakdown →